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ABSTRACT
Narcolepsy is a sleep disorder known and studied about from time to time is a sleep disorder characterized by a 
combination of myriad of symptoms including excessive day time sleepiness with recurrent irresistible sleep attacks , 
hypnogogic hallucinations ,hypnopompic hallucinations ,sleep paralysis and cataplexy (sudden and bilateral loss of 
muscle tone.1  Narcolepsy may present it self long with cataplexy or without cataplexy. The pathogenesis behind 
narcolepsy is found to be due to degeneration of hypocretin/orexin secreting neurones in the central nervous system 
due to disorder of human leukocyte antigen DQB1*0602.Narcolepsy is a deblitating disorder which causes intense 
functional impairment and hampers quality of life. Diagnosing narcolepsy can be challenging with help from clinical 
signs and symptoms , serum hypocretin/orexin levels and certain laboratory sleep tests . A definative cure for 
narcolepsy is not known , but pharmacological therapy with certain lifestyle changes are the main options.
R E V I E W  A R T I C L E
INTRODUCTION
Narcolepsy a REM sleep disorder is characterized by 
excessive day time sleepiness.The presentation is 
variable and not all patient show the classic tetrad2 
.Variable symptoms include blurry vision, loss of 
memory ,loss of concentration  ,fragmented night sleep 
and automated behavior.3,4,5,6 Narcolepsy may be found 
in association with cataplexy or without and is 
associated with other sleep disorder like obstructive 
sleep apnea  and REM sleep behavior disorder7,8. The 
epidemiology of narcolepsy is highly variable with 
prevalence of about 47/100000 in five European 
countries like  Spain ,Portugal ,Italy , Germany and UK 
9. In counties like japan and israel the prevalence has 
been found to be 0.16% and 0.0002% respectively 
.10,11 IN countries like US prevalence rates 
19-56/100000 have been found.12 The variances in 
prevalence could be attributed to the difference in the 
frequency of the HLA DQB1*0602 phenotype amongst 
the different geographical populations.13 The  data on 
incidence of narcolepsy is limited with 0.74/100000 
persons -year with However there is lack of suffecient 
data in establising routine HLA screening as a 
diagnostic test. Hypocretin 1 and 2 also known as 
orexin A and orexin B neurotramsitters  produced by the 
hypothalamus help regulate sleep wake cycle (21) and 
defecincy is found associated with narcolepsy leading 
to abnormalities in REM sleep and excessive day time 
sleepiness22.Some receptor mutations such as 
mutated hypocretin receptor 2 have also been found.23 
Another important cause for narcolepsy is 
autoimmunity the details of which are mentioned as 
follows. The Tribbles homolog 2 (Trib2) transcript has 
been shown to be abudant in the hypocretin neurones 
of engineered mice.24 both narcolepsy with cataplexy 
and 1.37 per 100000 with both narcolepsy with 
cataplexy and narcolepsy without cataplexy with (1.72 
for men and 1.05) for women. The incidence rate was 
highest in the second decade of life  followed by third , 
fourth and fifth decadesrespectively.14  Most cases of 
narcolepsy are sporadic with some with familial 
clustering. Enviornmental factors have also played a 
role with with 25% to 31% concordance in monozygotic 
twiins.(15) People who are first degree relatives are 10 to 
40 times more vulnerable  to develop narcolepsy 
compared to general population.16 Rescent studies 
have also established a close link between narcolepsy 
and streptococcal infections17 and H1N1  vaccination 
18. About 85% people having symptoms of narcolepsy 
with cataplexy are positive for HLA DQB1*0602, often 
simultaneously with  HLA DR2 (DRB1*1501) and only 
50 % with narcolepsy only have a positive HLA 
DQB1*0602 haplotype.19 Some rare cases lack the 
classic HLA DQB1 20. 
AUTOIMMUNITY IN NARCOLEPSY:
It has been established that people who lack the cells 
that produce hypocretin also known as Orexin,have 
Narcolepsy. Hypocretin, which is produced by the 
lateral hypothalamus, helps to regulate the sleep-wave 
cycles.The loss of 90% of hypocretin producing neurons 
leads to a significant decrease in hypocretin levels in 
the cerebrospinal fluid.Narcolepsy has been found to 
have a strong predisposition with MHC DQB1*06:02 
and T cell Receptor polymorphisms 25-28 that includes 
bystander activation and molecular mimicry. 
Professor Emmanuel Mignot (a professor of Psychiatry 
at  Stanford University) was the first to discover that 
Narcolepsy was caused by a loss of hypocretin 
synthesizing neurons. One evidence was the presence 
of genetic predisposition to autoimmune disease in 
patients with narcolepsy with human leukocyte 
antigens (HLA). In addition to this a second phenomena 
which is present in all autoimmune disease was 
discovered: A triggering or Inciting event.Over the past 
decade an increase in narcolepsy after an Influenza 
H1N1 infection and its vaccination strongly supports 
the disease’s autoimmune etiology. This became clear 
when researchers from multiple countries found the 
incidence of narcolepsy following vaccinations with 
Pandemrix against the H1N1 strain of influenza in 
2009.The results showed that there was a three-fold 
increase in incidence in Sweden29 and a 12-fold 
increase in incidence was recorded in Finland30. Other 
countries like England31,Norway32 and France33 also 
showed significant rise in the incidence of Narcolepsy.
A study in 2011 which was co-authored by Mignot also 
showed increased incidence of Narcolepsy showing a 
3-fold increase in china following a flu vaccination 
which he had mentioned and published in his  Annals 
of neurology.He also said that nearly 98% of the 
narcleptics had associations with HLA genes that are 
only known to be found in 25% of the world’s 
population34. However no rise in incidence was 
recorded in the USA following Pandemrix vaccination35. 
However, having said all this, researchers are yet to find 
a confirming proof that Narcolepsy is indeed an 
Autoimmune disease..
DISCUSSION:
Diagnosis; Narcolepsy is not a common sleep disorder 
but researchers and clinical physicians have had some 
difficulty of diagnosing this sleep disorder.Individuals 
thought of having narcolepsy are advised by their 
primary care physicians to see a sleep specialist in 
sleep centers where the disorder is mostly diagnosed 
using Two tests:The polysomnogram or the multiple 
sleep latency test.
1. The PSG (Polysomnogram) requires the patient to 
sleep overnight at the sleep center during which the 
test records the level of brain activity,heart rate and the 
blood pressure.A PSG study can tell a patient of how 
quickly he/she falls asleep,the onset of REM (Rapid eye 
movement) as soon as the patient fall asleep and how 
often he/she wakes up during the sleep cycle.
2. A Multiple sleep latency test is a daytime sleep study 
(vs a PSG) and hence measures the level or the 
intensity of sleep the patient is in. A person is made to 
sleep for every two hours for a duration of 20 mins 
every time and the technician tells how quickly a person 
is able to fall asleep,at what time different stages of a 
sleep cycle are encountered and exactly how sleepy a 
person is upon awakening.
3. The Hypocretin level measurement was a test the 
measured the level of hypocretin but is no longer used 
in the diagnosis of narcolepsy since it requires a lumbar 
punture (spinal tap) to be performed. It was used to 
show low levels of hypocretin which was diagnostic of 
narcolepsy Type 1 irrespective of the presence or 
absence of cataplexy.
Treatment:
Narcolepsy is a lifetime sleep disorder and narcoleptic 
patients may have to be on a lifetime treatment. 
Treatment modalities have been categorised into 
Nonpharmacologic and pharmacologic options based 
on the onset,duration and frequency of the features of 
this disorder.
1.Non-Pharmacological Approach to Narcolepsy:
One of the most important aspects of the treatment for 
narcolepsy is Sleep hygiene. This comprises of having 
regular sleep of 7.5-8 hours of sleep as well as having 
regular timed naps during the day. Adults with 
Narcolepsy need to have special consideration such as 
being provided with emotional support and counselling 
to both the patient and their attendants. They should 
be questioned and evaluated for possible cases of 
Alcohol or drug abuse,.Family conflict,depression in the 
family can also have a potentiating effect on the 
symptoms of Narcolepsy..Workaholics should be 
advised to avoid having jobs that require long hours of 
labour or official work.They should be advised to have 
scheduled naps prior to long drives.Heavy food and 
alcohol intake should also be minimized as they can 
induce sleep hence exacerbating and worsening the 
EDS. Broughton and Murray had mentioned in their 
study in 2006,that certain behavioral stimulation had 
been successful in 6 out of 13 patients.Such 
behavioral simulation included patient positional 
changes such as standing rather than sitting,movement 
in their daily routines,going out into the external 
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environment,having a cooler environment and a 
louder and more lively environment with a higher 
background noise 36. Studies over the years have 
shown that smokers take an extensive time frame to 
fall asleep hence,narcoleptics should be offered ways 
to reduce smoking or should be offered appropriate 
substitutes.37 Children with narcolepsy may need to 
be monitored with some care as well. Avoidance of 
food or beverages high in refined sugars has shown to 
reduce daytime sleepiness. Participation in sports and 
physical activities is advised to reduce the occurence 
of the symptoms of this disorder amongst adolescent 
and teens. Patients should be advised to have and 
follow strict napping for 15-20 minutes 2 to 3 times 
per day. Other helpful techniques include 
manipulation of the temperature of body/skin 
(keeping the extremities cooler can be 
useful),consumption of hot food or beverages during 
daytime. CBT (Cognitive Behavioral Therapy) can be 
useful as it targets the behavioral symptoms of 
narcolepsy. It has been found to be very effective in 
treating medication non-adherence and 
noncompliance.Features like depression and 
hypersomnia is being successfully treated by CBT.38,39
2. Pharmacological treatment:
The management of narcolepsy is primarily based on 
the symptomatic presentation of the patient.The most 
commonly found symptom of narcolepsy is Excessive 
daytime somnolence that can lead to automobile 
accidents and even death due to a massive injury. 
Hence,drugs that combat EDS are commonly 
prescribed such as Modafinil and Sodium Oxybate 
that promote wakefulness by targeting the 
neurotransmitters such as dopamine and 
norepinephrine as well as antihistaminic 
pathways.They increase the levels of dopamine that 
leads to increased wakefulness time that can 
counteract the EDS.40,41,42. Some studies conducted 
on a larger scale have shown that Modafinil has been 
successful in treating feelings of sleepiness in 
narcoleptic patients which was quantified on the 
Epworth Sleepiness Scale. Modafinil also helped to 
improve the wakefulness in patients which was 
recorded on the Maintenance of Wakefulness 
test.43,44. Unlike Modafinil,Sodium oxybate is a 
relatively newer medication also known as GHB 
(GABA hydroxybutyric acid) and is very effective in 
treating EDS as well as cataplexy.It is reported to 
improve the quality of nocturnal sleep that leads to 
improved daytime hours.It has been reported to 
markedly reduce the number of sleep attacks and 
sleep paralysis as well by increasing slow wave 
sleep.BUt similar to stimulants it has been associated 
with abuse,withdrawal side effects and dependance. 
40,42,45,46,47,48,49. Studies performed over the past years 
on a large number of patients have shown that 
sodium oxybate has been successful in reducing 
cataplexy by 70-85%.47. Stimulants (Amphetamines 
and Dextromethorphan and in some cases 
Methylphenidate) are used as an ancillary treatment 
for narcolepsy in cases when the first line treatment is 
no longer effective. They enhance alertness by 
altering the monoaminergic pathways specifically 
targeting dopamine and norepinephrine. 
However,these stimulants can cause potential side 
effects such as arrhythmias,psychiatric disturbances 
and addictions. Hence,for these reasons they are 
primarily prescribed for treating Disorders with 
attention deficits (ADHD) or impulsiveness. 
Methylphenidate has also been associated with 
weight loss and insomnia and cannot be prescribed to 
anorexics or bulimics.50,51.
CONCLUSION
The article therefore provides a snapshot on the 
pathophysiology and the various treatment options 
available for narcolepsy further reviews and article can 
aid understanding this sleep disorder in detail 
especially in relation with other chronic disease  .
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scheduled naps prior to long drives.Heavy food and 
alcohol intake should also be minimized as they can 
induce sleep hence exacerbating and worsening the 
EDS. Broughton and Murray had mentioned in their 
study in 2006,that certain behavioral stimulation had 
been successful in 6 out of 13 patients.Such 
behavioral simulation included patient positional 
changes such as standing rather than sitting,movement 
in their daily routines,going out into the external 
4 8P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
environment,having a cooler environment and a 
louder and more lively environment with a higher 
background noise 36. Studies over the years have 
shown that smokers take an extensive time frame to 
fall asleep hence,narcoleptics should be offered ways 
to reduce smoking or should be offered appropriate 
substitutes.37 Children with narcolepsy may need to 
be monitored with some care as well. Avoidance of 
food or beverages high in refined sugars has shown to 
reduce daytime sleepiness. Participation in sports and 
physical activities is advised to reduce the occurence 
of the symptoms of this disorder amongst adolescent 
and teens. Patients should be advised to have and 
follow strict napping for 15-20 minutes 2 to 3 times 
per day. Other helpful techniques include 
manipulation of the temperature of body/skin 
(keeping the extremities cooler can be 
useful),consumption of hot food or beverages during 
daytime. CBT (Cognitive Behavioral Therapy) can be 
useful as it targets the behavioral symptoms of 
narcolepsy. It has been found to be very effective in 
treating medication non-adherence and 
noncompliance.Features like depression and 
hypersomnia is being successfully treated by CBT.38,39
2. Pharmacological treatment:
The management of narcolepsy is primarily based on 
the symptomatic presentation of the patient.The most 
commonly found symptom of narcolepsy is Excessive 
daytime somnolence that can lead to automobile 
accidents and even death due to a massive injury. 
Hence,drugs that combat EDS are commonly 
prescribed such as Modafinil and Sodium Oxybate 
that promote wakefulness by targeting the 
neurotransmitters such as dopamine and 
norepinephrine as well as antihistaminic 
pathways.They increase the levels of dopamine that 
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counteract the EDS.40,41,42. Some studies conducted 
on a larger scale have shown that Modafinil has been 
successful in treating feelings of sleepiness in 
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sleep paralysis as well by increasing slow wave 
sleep.BUt similar to stimulants it has been associated 
with abuse,withdrawal side effects and dependance. 
40,42,45,46,47,48,49. Studies performed over the past years 
on a large number of patients have shown that 
sodium oxybate has been successful in reducing 
cataplexy by 70-85%.47. Stimulants (Amphetamines 
and Dextromethorphan and in some cases 
Methylphenidate) are used as an ancillary treatment 
for narcolepsy in cases when the first line treatment is 
no longer effective. They enhance alertness by 
altering the monoaminergic pathways specifically 
targeting dopamine and norepinephrine. 
However,these stimulants can cause potential side 
effects such as arrhythmias,psychiatric disturbances 
and addictions. Hence,for these reasons they are 
primarily prescribed for treating Disorders with 
attention deficits (ADHD) or impulsiveness. 
Methylphenidate has also been associated with 
weight loss and insomnia and cannot be prescribed to 
anorexics or bulimics.50,51.
CONCLUSION
The article therefore provides a snapshot on the 
pathophysiology and the various treatment options 
available for narcolepsy further reviews and article can 
aid understanding this sleep disorder in detail 
especially in relation with other chronic disease  .
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